India Ropes In American Novavax For New Vaccine
Novavax is going to be the new kid on the block when it comes to Covid-19 vaccine in India. The American company has tied up with India’s Serum Institute of India. It is on fast-track approval mode and undergoing its 2-3 stage trials to be administered on kids as well.
There are indications of a third wave that is going to hit children in India and vaccines that are currently in use are not fit for administering on children.
Apparently, this development comes after the External Affairs Minister visited the White House, at a time that states were independently seeking supply from various American biotechnology companies.
There are confirmed reports that 30 crore Novavax shots (five crore a month) could be made available during September-December this year and the number may just rise.
The vaccine is being launched in India under the name of Covavax at it will start production to go into market only September. Ironically, according to an official statement by Novavax, its worldwide launch of the COVID-19 shot will get pushed beyond Q3 2021 (July to September).
It might just be getting clearance for emergency use in India. This could be dependent a lot on India’s growing trade relations with the US.
As far as Covaxin in concerned, it is also looking at receiving clearance for pediatric use. As of now, no vaccine has been given clearance by WHO for pediatric use.